Early Trials: Johnson & Johnson COVID Vaccine Prompts Immune Response

The Johnson & Johnson vaccine, using an adenovirus to deliver the coronavirus spike protein, has shown promising results in early clinical trials. It generates an immune response in both young and elderly volunteers, with 90% producing antibodies within 29 days. The vaccine is advantageous due to its single-dose nature and less stringent storage requirements compared to Pfizer and Moderna vaccines. Phase 3 trials will provide more insights, and J&J plans to seek FDA emergency approval soon.

What is the significance of the Johnson & Johnson vaccine being a 'one and done' vaccine?

What are the expected outcomes from the phase 3 trial of the Johnson & Johnson vaccine?